藥用明膠市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年，全球藥用明膠市場規模達13億美元，預計到2034年將以5.8%的複合年成長率成長，達到23億美元。膠囊和片劑等口服固體劑型的消費量不斷成長，有力地推動了市場發展勢頭。隨著慢性病發生率的上升，製藥業也隨之擴張，對明膠基輔料的需求也持續成長。明膠能夠包覆多種活性藥物成分，是硬膠囊和軟膠囊配方中的關鍵成分。它與親水性和親脂性化合物的優異相容性，提高了最終產品的生物利用度，使其成為現代藥物傳遞中不可或缺的輔料。

藥用明膠是一種精製蛋白質，源自於動物骨骼和皮膚等膠原蛋白來源。它因其獨特的物理和化學特性而被廣泛使用，包括熱可逆性、生物相容性和易消化性。這些特性使其成為製造膠囊、包衣劑、傷口敷料和其他醫療製劑的理想材料。隨著製藥公司越來越注重提高產品的功效和穩定性，明膠作為輔料的作用比以往任何時候都更加重要。創新藥物劑型的穩定發展和先進給藥系統的開發也促使整個產業對藥用級明膠的依賴日益增加。藥用明膠的主要生產商在保持穩定的品質、遵守監管準則以及提供客製化解決方案以滿足不斷變化的配方需求方面發揮著至關重要的作用。

就產品類型而言，藥用明膠市場分為A型明膠和B型明膠。其中，B型明膠在2024年佔據主導地位，約佔整體市佔率的65.4%。其被廣泛採用的主要原因之一是其經濟高效的生產過程。 B型明膠通常經過鹼性水解處理，使其具有良好的特性，例如高熱穩定性和接近中性的pH值。這些特性使其特別適用於製藥用途，包括膠囊殼、薄膜包衣和注射。此外，其在藥品生產環境中的可預測性能確保了藥品的均勻性和質量，而這些是大規模藥品生產的關鍵參數。因此，對於尋求可靠性和多功能性輔料的配方師來說，B型明膠仍然是首選。

市場進一步細分，基於明膠的來源，包括牛、豬、魚和家禽。其中，牛源明膠在2024年佔最大佔有率，市佔率達48.4%。預計預測期內，該市場將以6.1%的複合年成長率成長。由於廣泛的養牛業，牛源明膠擁有穩定且充足的原料供應。其強大的凝膠強度、高黏度以及在不同加工條件下優異的穩定性，使其特別適用於各種製藥應用。這些應用不僅包括膠囊製造，還可用於血漿擴容劑和傷口護理產品。牛明膠始終如一的品質和可重複性進一步提升了其在確保標準化配方結果方面的價值。

從區域來看，北美在全球藥用明膠市場中佔據主導地位，收入貢獻最高，2024 年佔 38.2% 的市場佔有率。該地區的主導地位主要歸功於其先進的藥品生產基礎設施以及嚴格且支持性強的合規環境。由於明膠性能可靠且適應性強，北美製藥公司積極將其整合到各種劑型中。此外，製藥業持續的研發投入也促進了基於明膠的先進藥物輸送解決方案的出現。完善的合約製造組織生態系統進一步增強了區域市場，有助於滿足國內和全球需求。

全球藥用明膠市場呈現中等整合格局。這些參與者憑藉全球製造能力、嚴格遵守品質標準以及持續的產品開發創新，保持著競爭優勢。他們專注於提昇明膠的功能特性，以用於特殊配方（例如控釋膠囊或可吸收手術輔助器具），從而拓展了市場深度。同時，發展中地區的新進業者也透過提供經濟高效的明膠選擇、建立認證設施以及瞄準滲透率較低的市場的新興需求，展現出其影響力。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 膠囊和軟膠囊的需求不斷成長
    • 老年人口成長與慢性病負擔
    • 明膠在止血劑和傷口護理的應用
    • 疫苗和生物製劑產量不斷成長
  • 產業陷阱與挑戰
    • 動物源性明膠對人體的副作用
    • 植物性和合成替代品的出現
  • 市場機會
    • 在再生醫學和組織工程的應用
    • 發展中國家對藥用明膠的需求不斷成長
• 成長潛力分析
• 監管格局
• 技術進步
  • 當前的技術趨勢
  • 新興技術
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
  • 北美洲
  • 歐洲
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 擴張計劃

第5章：市場估計與預測：按類型，2021 - 2034 年

• 主要趨勢
• A型
• B型

第6章：市場估計與預測：按來源，2021 - 2034 年

• 主要趨勢
• 豬
• 牛
• 魚
• 家禽

第7章：市場估計與預測：按功能，2021 - 2034 年

• 主要趨勢
• 穩定劑
• 增稠劑
• 膠凝劑
• 成膜
• 黏附性
• 其他功能

第8章：市場估計與預測：按應用，2021 - 2034 年

• 主要趨勢
• 膠囊
  • 硬膠囊
  • 軟膠囊
• 平板電腦
• 可吸收止血鉗
• 其他應用

第9章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Capsugel (Lonza)
• Funingpu Biotechnology
• Gelita AG
• India Gelatine & Chemicals
• ITALGEL
• Junca Gelatines
• Lapi Gelatine
• Nitta Gelatin
• Rousselot (Darling Ingredients)
• Sterling Biotech
• PB Leiner (Tessenderlo Group)
• Trobas Gelatine
• Weishardt Group
• Xiamen Gelken Gelatin

The Global Pharmaceutical Gelatin Market was valued at USD 1.3 billion in 2024 and is estimated to grow at a CAGR of 5.8% to reach USD 2.3 billion by 2034. Market momentum is being strongly driven by the growing consumption of oral solid dosage forms like capsules and tablets. As the pharmaceutical industry expands in response to rising incidences of chronic diseases, the need for gelatin-based excipients continues to rise. Gelatin is a key component used in the formulation of both hard and soft capsules, thanks to its ability to encapsulate a wide range of active pharmaceutical ingredients. Its superior compatibility with hydrophilic and lipophilic compounds enhances the bioavailability of the final product, making it indispensable in modern drug delivery.

Pharmaceutical gelatin is a refined protein derived from collagen sources such as animal bones and skins. It is commonly used for its unique physical and chemical properties, including thermal reversibility, biocompatibility, and ease of digestibility. These features make it an ideal material for manufacturing capsules, coating agents, wound dressings, and other medical formulations. With pharmaceutical companies increasingly focused on improving the efficacy and stability of their products, gelatin's role as an excipient has become more important than ever. The steady shift toward innovative drug formats and the development of advanced delivery systems have also contributed to the growing reliance on pharmaceutical-grade gelatin across the industry. Major producers of pharmaceutical gelatin play a crucial role in maintaining consistent quality, adhering to regulatory guidelines, and offering tailored solutions to meet evolving formulation needs.

In terms of product types, the pharmaceutical gelatin market is divided into type A and type B gelatin. Among these, type B gelatin held a dominant position in 2024, accounting for approximately 65.4% of the overall market share. One of the main reasons for its broad adoption is its cost-effective manufacturing process. Type B gelatin is typically processed through alkaline hydrolysis, which imparts favorable characteristics such as high thermal stability and a nearly neutral pH. These properties make it especially suitable for pharmaceutical uses, including capsule shells, film coatings, and injectable formulations. Moreover, its predictable performance in drug manufacturing environments ensures uniformity and quality, which are critical parameters in large-scale pharmaceutical production. As a result, type B gelatin continues to be a preferred choice among formulators seeking reliability and versatility in excipient performance.

The market is further segmented based on the source of gelatin, which includes bovine, porcine, fish, and poultry. Among these, gelatin derived from bovine sources represented the largest segment in 2024, holding a market share of 48.4%. It is anticipated to expand at a CAGR of 6.1% during the forecast period. Bovine-derived gelatin benefits from a stable and abundant supply of raw materials, thanks to widespread cattle farming. Its strong gelling strength, high viscosity, and excellent stability across processing conditions make it particularly suitable for a wide array of pharmaceutical applications. These include not just capsule manufacturing but also uses in plasma expanders and wound care products. The consistent quality and reproducibility of bovine gelatin further enhance its value in ensuring standardized formulation outcomes.

Regionally, North America led the global pharmaceutical gelatin market with the highest revenue contribution, securing a 38.2% market share in 2024. The dominance of this region is largely attributed to its advanced pharmaceutical production infrastructure and a highly regulated yet supportive compliance environment. Pharmaceutical companies in North America actively integrate gelatin into a variety of dosage forms due to its proven performance and adaptability. Additionally, ongoing investment in research and development across the pharmaceutical landscape supports the emergence of sophisticated gelatin-based drug delivery solutions. A well-established ecosystem of contract manufacturing organizations further strengthens the regional market, helping meet both domestic and global demand.

The global pharmaceutical gelatin market exhibits a moderately consolidated structure. These players maintain their competitive edge through global manufacturing capabilities, strict adherence to quality standards, and consistent innovation in product development. Their focus on enhancing gelatin's functional properties for use in specialized formulations-such as controlled-release capsules or absorbable surgical aids-adds depth to the market. At the same time, newer entrants in developing regions are making their presence felt by providing cost-efficient gelatin options, establishing certified facilities, and targeting emerging demand across underpenetrated markets.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Type trends
  • 2.2.3 Source trends
  • 2.2.4 Function trends
  • 2.2.5 Application trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising demand for capsules and softgels
    • 3.2.1.2 Expanding elderly population and chronic disease burden
    • 3.2.1.3 Use of gelatin in hemostatic agents and wound care
    • 3.2.1.4 Growing vaccine production and biologics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects associated with animal-derived gelatin in humans
    • 3.2.2.2 Emergence of plant based and synthetic alternatives
  • 3.2.3 Market opportunities
    • 3.2.3.1 Use in regenerative medicine and tissue engineering
    • 3.2.3.2 Rising demand for pharma gelatin in developing countries
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technological advancements
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Type A
• 5.3 Type B

Chapter 6 Market Estimates and Forecast, By Source, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Porcine
• 6.3 Bovine
• 6.4 Fish
• 6.5 Poultry

Chapter 7 Market Estimates and Forecast, By Function, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Stabilizers
• 7.3 Thickeners
• 7.4 Gelling agents
• 7.5 Film forming
• 7.6 Adhesion
• 7.7 Other functions

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Capsules
  • 8.2.1 Hard capsules
  • 8.2.2 Soft capsules
• 8.3 Tablets
• 8.4 Absorbable hemostats
• 8.5 Other applications

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Capsugel (Lonza)
• 10.2 Funingpu Biotechnology
• 10.3 Gelita AG
• 10.4 India Gelatine & Chemicals
• 10.5 ITALGEL
• 10.6 Junca Gelatines
• 10.7 Lapi Gelatine
• 10.8 Nitta Gelatin
• 10.9 Rousselot (Darling Ingredients)
• 10.10 Sterling Biotech
• 10.11 PB Leiner (Tessenderlo Group)
• 10.12 Trobas Gelatine
• 10.13 Weishardt Group
• 10.14 Xiamen Gelken Gelatin